• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 126

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial...

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety...

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform...

PT365 – Dr. Jennifer Montjoy – KAP: Self-Agency Through Intention, Titration,...

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol...

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit...

Acid for Anxiety: Fast and Lasting Anxiolytic Effects of LSD

PT364 – Jamie Wheal – Burning Man, Psychedelic Maturity, and Radical...

1...125126127...292Page 126 of 292

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©